Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DYAD MEDICAL, INC.
- Proposal award date
- 2019-02-04
- Contract end date
- 2021-01-31
- UEI
- JCJ8YJYLG1P1
- Solicitation number
- PA18-574
- Topic code
- NHLBI
Research abstract
Project Summary.
Dyad Medical, Inc. will create intravascular Optical Coherence Tomography (IVOCT) software for clinical, live
time determination of stent apposition and for offline analysis of stent implantation. Every year, 100s of
thousands of patients in the US are treated with intravascular stents creating an opportunity for both solutions.
Although advancements such as drug eluting metal stents hinder restenosis, there remains significant room for
improvement. Stent design parameters include drug, material (bioresorbable vs metal), polymer composition,
coatings to stimulate cell coverage, etc. To optimize designs, sensitive, in vivo assessments are needed for
preclinical and clinical evaluations. IVOCT is the lone imaging modality with the resolution and contrast to meet
this challenge. Dyadandapos;s automated software solution promises to drastically cut stent image analysis from 6-16
hrs of manual analysis to less than 2 minutes per single stent, as demonstrated in our Phase I feasibility
results. We also demonstrated stent strut detection accuracy andgt;88%, classification accuracy andgt;88%, and stent
and vessel areas with accuracy andgt;90%. In addition to faster analysis, we will eliminate inter-analyst variability
and errors, which in turn have the potential to significantly improve cliniciansandapos; ability to accurately assess and
interpret stent position and integrity in real time. Cardiology analysts will be able to provide instant feedback to
physicians, presenting the number and location of malapposed struts in 3D, empowering their decision making
on the need for additional dilatation with a larger balloon or higher pressure, or whether patient needs to stay
on anti-platelet regimen or be taken off in order to minimize bleeding risk. For purposes of research, clinical
trials or stent design development, our software will improve reproducibility, increase accuracy, and harmonize
analysis. In this follow on Phase II study, we will develop enhanced algorithms, optimize software usability,
develop and test several user interfaces (UIs) in collaboration with the Core Lab at the University Hospitals.
We will test and validate the functionality and performance of software using image data sets from multiple
sources, increasing robustness of our approach. Phase II will enable us to develop a highly functional and
usable software ready for commercial deployment. It will facilitate the use of our software in the clinic as part of
an initial trial in the cath lab.Project Narrative.
Dyad Medical will develop software tool for rapid, automated in vivo assessment of intravascular stents,
currently the treatment of choice for 100s of thousands of patients, suffering from ischemic heart disease, in
the US each year. Our methods will enable optimization of stent technologies and improved deployment of
stents for improved treatment of vascular disease.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
3 SBIR/STTR records share this UEI (2017–2023). Reported award amounts total $2,864,326. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards